Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 9039 results

  1. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development Reference number: GID-TA10393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Abdominal aortic aneurysm

    Awaiting development Reference number: GID-QS10035 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Severe mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  6. Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date:  17 December 2027

    NICE guideline
    In development

  8. Spinal Cord Stimulation Effective for HIV Neuropathy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Endovascular Arch Repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    In development Reference number: GID-TA11743 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  11. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  13 October 2026

    In development

  12. Ruxolitinib for treating moderate atopic dermatitis ID6602

    In development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  14. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development